Key result
Statins were initially associated with decreased mortality among cardiogenic shock survivors, but this association was no longer significant after adjustment.
Why the study?
Does statin prescription reduce hospital mortality in patients surviving the initial phase of cardiogenic shock?
Does statin prescription reduce hospital mortality in patients surviving the initial phase of cardiogenic shock?
Answers are grounded in this paper and cite their sources.
The apparent mortality benefit of statins in acute cardiogenic shock may be driven by survival and confounding biases, underscoring the need for randomized controlled trials.
To the Editor, Sim et al. 1) should be congratulated for their meticulous analysis of a large and complete dataset following patients with acute myocardial infarction for more than 2 years.They concluded from propensity score analyses that statins were associated with decreased in-hospital mortality and 12-month adverse cardiac events.Their conclusions are debatable.First, the inclusion criterion-Killip 4, a proxy for cardiogenic shock (CS)-is an issue.The population does not reflect real CS as severity indicators (acute kidney injury, <5%; mechanical ventilation, 38%) and mortality (-23%) are low.Furthermore, major prognostic markers such as extra-renal replacement, serum lactates and catecholamine use are lacking.Thus, the study evaluates the prognosis impact of statin prescription in "serious" ST segment elevation myocardial infarction (STEMI) (intraaortic balloon pump, 28%; cardiac arrest, 18%) with a poor definition of CS.2)The Kaplan Meyer curve shows that most deaths occur early during the hospital stay, and this is an obvious survival bias.Patients with severe presentation and rapid death may not have received statins.In a large registry spanning over three decades, patients with STEMI with CS were less likely to receive optimal medical treatment with betablockers, aspirin and lipid lowering agents than those without CS (20% vs. 31%, p<0.001). 3)In order to deal with survivor bias, we examined statin prescription in patients with ischemic CS surviving the initial phase of CS.In our retrospective study of 249 patients with CS of varying etiology, hospital mortality was high,
No takes yet. Share an insight, caveat, or question.
Sébastien Champion (2014) conducted a letter in Cardiogenic shock (n=249). Statins vs. No statins was evaluated on Hospital mortality (p=0.01). Statins were initially associated with decreased mortality among cardiogenic shock survivors, but this association was no longer significant after adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: